Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications - cervical ...

Merz North America announced that Xeomin (incobotulinumtoxinA) has been approved by the Food and Drug Administration (FDA) for the treatment of upper limb spasticity in adults. Merz North America ...

VANCOUVER -- Guidelines for the use of botulinum toxin in various neurological disorders are getting an update, with the best evidence supporting the use of some formulations in spasticity and chronic ...

DYSPORT (abobotulinumtoxinA) 500Units single-use vial for injection by Ipsen Ipsen announced that the Food and Drug Administration (FDA) has approved Dysport (abobotulinumtoxinA) injection for the ...

Dystonia is a neurological disorder causing involuntary muscle contractions and abnormal postures. Botulinum toxin (e.g., Botox) is the gold-standard, first-line treatment for focal dystonias, which ...

This is a preview. Log in through your library . Abstract This study was conducted to describe the clinical characteristics and long-term outcome in woodwind instrumentalists with focal dystonia.

It was spring 2014, and I was working for the federal forest service. Increasingly, I found myself holding my chin to keep my head from shaking when I worked at my computer or during meetings. I also ...

- Revance now expects to report topline results from JUNIPER trial in early 2021 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on ...